- Home
- SGMT vs HRTX Comparison
SGMT vs HRTX Comparison
Compare SGMT & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | HRTX |
|---|---|---|
| Founded | 2006 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.7M | 203.5M |
| IPO Year | 2023 | 1987 |
Fundamental Metrics
Financial Performance| Metric | SGMT | HRTX |
|---|---|---|
| Price | $5.90 | $1.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $29.71 | $4.50 |
| AVG Volume (30 Days) | 622.5K | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $155,097,000.00 |
| Revenue This Year | N/A | $8.98 |
| Revenue Next Year | N/A | $11.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.60 |
| 52 Week Low | $1.73 | $1.00 |
| 52 Week High | $11.41 | $2.68 |
Technical Indicators
Market Signals| Indicator | SGMT | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.38 | 54.20 |
| Support Level | $5.92 | $1.26 |
| Resistance Level | $6.33 | $1.40 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 11.16 | 56.01 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.